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In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have
not demonstrated signiﬁcant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The
neutral ﬁndings may have been due to experimental design issues, such as: maintenance on aggressive
cardiovascular drug treatment overshadowing the beneﬁts of LC omega-3s, high background LC omega-3
intake, too few subjects in the study, treatment duration too short, insufﬁcient LC omega-3 dosage,
increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the
subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected
to produce beneﬁts. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical
trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects
of experimental design that should be considered when planning clinical studies related to EPA and DHA
and potential cardiovascular beneﬁts.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
At the 11th Congress of the International Society for the Study
of Fatty Acids and Lipids (ISSFAL), the Global Organization for EPA
and DHA Omega-3s (GOED) sponsored a workshop on conducting
long chain omega-3 (LC omega-3) clinical trials with cardiovas-
cular outcomes. The goal of the workshop was to gain a better
understanding, from scientists intimately involved in LC omega-3
fatty acid (EPA/DHA) research, about aspects of experimental
design that should be considered when planning clinical studies
related to EPA/DHA and potential cardiovascular beneﬁts.
The inspiration for the workshop was frustration among GOED
personnel during recent years with the publication of a number of
cardiovascular studies of EPA/DHA demonstrating neutral results,Ltd. This is an open access article u
and DHA Omega-3s (GOED),
USA. Tel.: þ1 801 746 1413;
e).but with less than optimal experimental designs [1–7]. While any,
or all, of these studies could have been neutral because there are
no cardiovascular beneﬁts associated with increased EPA/DHA
intake, given the past positive ﬁndings [8–11], that is not con-
sidered to be likely. Some studies with neutral ﬁndings have been
heavily publicized, gaining widespread attention, yet the ﬁndings
are rarely put into proper context, thus they may be mis-
interpreted or the ﬁndings exaggerated. The conclusion from this
becomes that LC omega-3s (EPA/DHA) are not “heart healthy.” One
danger of this is that consumers become confused, under-
standably, and so stop eating ﬁsh and/or taking LC omega-3
supplements.
In contrast to earlier investigations [8–11], some recent studies
[1–7] have not demonstrated signiﬁcant effects of the LC omega-3
fatty acids EPA and DHA on cardiovascular disease (CVD) event
risk. Neutral ﬁndings from these more recent studies may be
attributable to a number of possible causes, including: main-
tenance on aggressive cardiovascular drug treatment over-
shadowing the beneﬁts of LC omega-3s, high background LCnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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too short, insufﬁcient LC omega-3 dosage, and increase in omega-6
fatty acid intake during the study. These issues were addressed
during the workshop. Five scientists with expertise in LC omega-3
fatty acids presented during the workshop and this review sum-
marizes their presentations in the order given.2. Statistical power considerations in the design of omega-3
trials with cardiovascular outcomes (Aldo Bernasconi, PhD)
There is a long history of clinical research showing that LC
omega-3 fatty acids have a cardio-protective effect. This research
includes both observational studies, of which there are a large
number, and several large randomized control trials (RCTs). One
surprising aspect of this research is that while the earlier RCTS
showed that consumption of fatty ﬁsh or of LC omega-3 supple-
ments have a clear beneﬁt for cardiovascular health, later studies
with similar design have found smaller effects, or failed to ﬁnd a
signiﬁcant effect.
The ﬁrst large RCT on this subject was the Diet and Reinfarction
Trial (DART), conclusions from which were published in 1989 [8].
The researchers recruited 2033 men who had recovered from a
myocardial infarction, and randomized them to receive advice on
three possible dietary changes: 1) to increase consumption of fatty
ﬁsh, 2) to increase the ratio of polyunsaturated to saturated fat, or
3) to increase cereal consumption. The study found that con-
sumption of two weekly servings of fatty ﬁsh not only reduced the
risk of death from ischemic heart disease (IHD), but also reduced
all-cause mortality by 29% compared with the results for those not
given advice about consuming fatty ﬁsh.
A large, open-label, RCT, the GISSI-Prevenzione trial [9], con-
ﬁrmed a protective effect of LC omega-3 fatty acids. In a group of
11,324 patients who had survived a recent myocardial infarction,
LC omega-3 fatty acid ethyl ester consumption (1 g/d) reduced the
risk of all-cause mortality, sudden death, and coronary death
compared with usual care. The ﬁndings of these two large studies
were concordant, suggesting that LC omega-3 fatty acids were
protective against cardiovascular mortality in patients who had
already suffered a myocardial infarction, and they supported
results from several prospective cohort studies. The ﬁndings from
these studies were reviewed by Harris et al. [12], who found that
LC omega-3 fatty acid consumption was associated with decreased
coronary heart disease mortality.
Later studies, on the other hand, have failed to ﬁnd these same
effects on mortality ([2–4], for example), reporting either evidence
of a much smaller protective effect, or no effect at all. This
development has caused confusion amongst consumers as to
whether fatty ﬁsh and LC omega-3s are “heart healthy.” As a result,
there is some debate about whether omega-3 supplements reduce
cardiovascular risk, and even about whether the dietary recom-
mendations to eat more ﬁsh are appropriate.
The reason for this apparent contradiction may be that
advances in the treatment and prevention of CVD have radically
changed the environment in which trials of EPA/DHA are con-
ducted. As a consequence, the effect of the LC omega-3 fatty acid
interventions seen in clinical trials has been reduced, and study
designs that were adequate even 20 years ago, now result in stu-
dies that are underpowered for the outcomes being investigated.
To understand why this is the case, one needs to examine some
aspects about the statistical framework used for hypothesis test-
ing, known as the Neyman–Pearson paradigm [13]. Under this
approach, before conducting an experiment the researcher choo-
ses a signiﬁcance value or p-value cutoff. This cutoff, usually
denoted by the Greek letter alpha, is a statement about the
acceptable risk of getting a false positive result. A researcherchoosing an alpha value of 0.01 is stating that, for this experiment,
he or she is willing to accept a 1% risk of a false positive result.
Along with the alpha level, the researcher will generally select a
desired statistical power (deﬁned as the probability of reaching a
true positive result), and select the number of participants and
other study design aspects accordingly. The choice of a particular
value for statistical power is a statement of the researcher's tol-
erance for false negative results. For example, if a researcher plans
an experiment to have 90% power, he is in fact stating that he is
willing to accept a 10% risk that the experiment will miss (fail to
declare statistical signiﬁcance at the speciﬁed alpha level) a result
that is, in fact, true.
There are several methods by which a researcher can increase
the power of an experiment, but they are not always practicable,
and each comes with a cost. It is important to note that these
associated costs are not always in terms of money or time. In a
sense, designing an experiment is a form of optimization: ﬁnding
the design that maximizes statistical power, while keeping the
costs at an acceptable level. Most of these methods fall into one of
the following categories:
1. Increasing the number of samples/subjects;
2. Increasing the effect of the intervention;
3. Reducing the sample/subject variability that is not caused by
the intervention;
4. Selecting a more appropriate statistical analysis.
2.1. Increasing the number of samples/subjects
Intuitively, the more samples or subjects used in a study, the
better and more precise all numerical estimates will be. This
makes it easier to discern an intervention effect amid the varia-
bility in the data, thereby increasing power. The obvious drawback
is that it is not always possible to recruit more subjects, either
because the population of interest that is willing and able to par-
ticipate is too small, or because increasing recruitment would
make the cost of the study prohibitive. Other potential costs may
include longer times to collect the necessary samples and data, the
need to develop collection, storage and analysis procedures to
handle the increased volume, or longer times from sample col-
lection to analysis, which may affect measurements of less stable
analytes.
Researchers must then strive to ﬁnd the right balance between
study size and cost. By relying on prior knowledge or assumptions
about a desirable intervention effect size, they can use statistical
power computations to estimate the number of samples necessary
to reach a pre-speciﬁed statistical power. Several common para-
digms for measuring the quality of reporting of clinical trials
require that the method used to decide the number of samples or
participants is described, but adherence to this requirement is low.
In a more specialized application, Guo et al. [14] examined articles
on cancer nursing RCTs published between 1984 and 2010 for
compliance to CONSORT [15] quality criteria, and estimated that
only 45% of these publications explicitly describe the method by
which sample size was selected. Turner et al. [16] estimated that
only 48% of articles based on RCTs published in medical journals
comply with this requirement.
One often overlooked aspect of increasing the number of sub-
jects is that the increased beneﬁts of adding participants diminish
as the number of subjects increases. This is best explained with an
example. Enns et al. [17] reviewed existing evidence and con-
ducted a meta-analysis to determine whether LC omega-3 fatty
acid supplementation reduces the risk of cardiovascular events in
patients with existing peripheral arterial disease (PAD) (Table 1).
The meta-analysis identiﬁes that LC omega-3 supplementation
confers a risk reduction from 5.6% to 3.9% (relative risk¼0.69), but
Table 1
Incidence of cardiovascular events in patients with existing peripheral arterial
disease receiving LC omega-3 fatty acids or placebo, as reported by the systematic
review and meta-analysis of [17]. The events for myocardial infarction and
cardiovascular death were obtained by combining the results of [18,19]. Results
for stroke and angina were obtained from [18,19], respectively.
Outcome LC Omega-3 fatty acids Control
Myocardial infarction 6/156 8/132
Cardiovascular death 5/156 7/132
Stroke 3/60 1/60
Angina 5/177 8/106
Total: 19/489 24/430
Fig. 1. Relationship between sample size and statistical power in a two-sample
proportion test to detect a reduction in incidence in the risk of cardiov-
ascular events from 5.6% to 3.9% in a high-risk population with Peripheral Arterial
Disease [17].
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relationship between the number of samples in each group (LC
omega-3 treated and control) and the statistical power in a study
of an outcome with these risks. If this protective effect is real, a
study with 2000 participants in each group would have a 71.4%
chance of detecting it with signiﬁcanceo0.05. Increasing the
number of participants to 3000 would increase this power to
87.2%. However, increasing the number of participants from 4000
to 5000 only increases the power from 94.7% to 97.9%. A
researcher must decide at what point the costs of adding addi-
tional subjects outweigh the beneﬁts of increased power.
One method used to achieve a higher number of participants is to
combine the results of previous trials by means of a meta-analysis.
Enns et al. [17] combined the results of two prior trials [18,19]. The two
studies were conducted in different populations, with different
demographic and socioeconomic proﬁles, genetic makeup, lifestyles,
diets and standards of medical diagnosis and care. Each one of these
differences introduces some noise into the ﬁnal data. In a way, a meta-
analysis is an attempt to achieve more power by increasing sample
size, but it comes at the cost of introducing variability into the ﬁnal
data set and often some difﬁculty in interpreting the results. Because
of this extra variability, a meta-analysis will not have higher power
than an RCT with an equal number of samples. In this case, both the
control and treated groups contain fewer than 500 participants, so the
power is well below 50%. In other words, even if supplementation
with LC omega-3 fatty acids confers a cardioprotective effect on
patients with PAD, a meta-analysis this size would have less than a
50% chance of detecting it at a signiﬁcance level of o0.05. The correct
interpretation of the results of this meta-analysis is that existing evi-
dence is insufﬁcient to determine whether or not intake of LC omega-
3 fatty acids prevents cardiovascular outcomes in this population.2.2. Increasing the effect of the intervention
An alternative approach to increase power is to modify the
intervention in order to magnify its effect. One extreme form of
this approach is seen in toxicology or drug safety experiments
performed on animal models. The laboratory animals are exposed
to much larger effective doses of the compound of interest than
any reasonably expected potential exposure in humans. For
obvious reasons, this is not always a practical or ethical approach
to use in trials involving human subjects, but some approaches can
still be used, including:
1. Increasing dosage where reasonable;
2. Extending the length of the intervention and follow-up;
3. Selecting study participants from higher-risk populations. Each
one of these approaches comes at a price. Extending the length
of a study, for example, increases its cost, and restricting it to a
higher-risk population may reduce the number of participants
or affect the generalizability of the results.
Increasing the dosage of LC omega-3 fatty acids used in clinical
studies is both a low-cost and safe method to potentially increase
study power. EPA and DHA have been established to be safe and
well-tolerated at levels well above those used in clinical studies. The
EFSA panel on Dietetic Products, Nutrition and Allergy has deter-
mined that intake levels of 5 g/d are safe [20], and the Norwegian
Scientiﬁc Committee for Food Safety considers 6.9 g/d [21] to be
safe. Neither of these two levels is seen as a maximum safe intake,
but rather an intake level that has been determined to be acceptable
– a potential maximum level would be higher than both, but has
never been determined. However, both of these intakes are many
times higher than habitual intakes and the levels of supplementa-
tion used in clinical trials (typically in the 500 mg to 1 g/d range).
It is important to note that, depending on the outcome of interest,
the effect of an intervention is not necessarily proportional to dosage,
and that the effect of supplementation will often depend on the
baseline characteristics of the population being studied. According to
Papanikolau et al. [22], the average intake of EPAþDHA among US
adults is 113 mg/d, of which 83 mg/d came from food, and the rest
from dietary supplements. There are no reliable estimates of
EPAþDHA intakes in the late 1980s, at the time in which DART was
being conducted, but ﬁsh intake estimates compiled by the U.S.
Environmental Protection Agency indicate that U.S. per capita ﬁsh
consumption has been steadily, albeit slowly, increasing since 1982
[23]. During DART [8], when the use of LC omega-3 supplements was
low, only a minimal amount of EPAþDHA would have come from
supplementation in the general population, so it is reasonable to
assume that EPAþDHA intake would have been somewhat lower
than 83 mg/d. Fig. 2, adapted from Mozaffarian and Rimm [24],
shows the relationship between EPAþDHA intake and the relative
risk of death caused by coronary heart disease (CHD).
Some observations are important:
1. There appears to be little beneﬁt in supplementing beyond
250 mg/d. This is an outcome for which increasing dosage
would not result in an increased treatment effect and
more power.
2. The effect of 1000 mg/d EPAþDHA supplementation on a
population with baseline intake of 83 mg/d (a reasonable esti-
mate of the U.S. adult intake at the time of DART, as described
above) would have a much larger protective effect than that
observed in the ORIGIN trial [4]. In other words, because of the
shifting baseline, studies with identical designs would have had
more statistical power 30 years ago. Newer studies require more
participants, longer follow-up times, or the use of other
approaches to increase their power.
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acids, people with a history of heart disease may eat more ﬁsh
and be more likely to take supplements, their habitual intake of
EPAþDHA may be higher than that of the general population. A
study using supplementation as the intervention would have a
small expected treatment effect, low power, and be unlikely to
detect a signiﬁcant protective effect. This may be part of the
reason why newer secondary prevention trials for cardiovascu-
lar outcomes have failed to detect a signiﬁcant effect.
There are some outcomes for which increasing the intervention
dose would result in an increased effect size. Fig. 3, taken from
Mozaffarian and Rimm [24] shows the relationship between
treatment dosage of EPAþDHA and the protective effect strength
for multiple cardiovascular outcomes. While an increase in dosageFig. 2. Pooled analysis of prospective cohort studies and randomized clinical trials of the
(2006) American Medical Association. All rights reserved. Adapted with permission from
Fig. 3. Relative protective effect for several cardiovascular outcomes, depending on in
reserved. Reprinted with permission from [24].would be unlikely to increase statistical power for a trial con-
cerning arrhythmia, or, as discussed above, CHD death, it would
have an effect for multiple other indications.
While increasing dosage does not always increase the treat-
ment effect, requiring participants to refrain from taking supple-
ments that are not part of the study, or selecting participants from
groups with lower baseline intake (as proposed by James et al.
[25]) would decrease EPAþDHA levels in the control group, and
may increase the treatment effect.
2.3. Reducing the sample/subject variability that is not caused by the
intervention
A third method to increase power is to reduce the variability
among samples that is not directly caused by the intervention. Inrelationship between EPAþDHA intake and relative risk for CHD death. Copyright ©
[24] with data marked from the ORIGIN trial [4].
tervention dosage. Copyright © (2006) American Medical Association. All rights
1.00 0.98 0.95
0.80*
0.00
0.20
0.40
0.60
0.80
1.00
1.20
HR for CHD vs.
control
p<0.05 vs. referent
Abbreviations:  CHD = coronary heart disease, EPA = eicosapentaenoic acid, HR = hazard ratio, 
JELIS = Japan EPA Lipid Intervention Study
Fig. 4. Relationship between on-treatment plasma EPA concentration (mg/mL) and
adjusted risk of major coronary events among participants in JELIS [40].
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plished by using animals of the same sex and strain, and by
making sure that the environments and diets of all groups are as
close to identical as possible. This cannot be done in studies
involving human subjects, but some control over unwanted
variability can be accomplished by selecting study participants of
the same sex, age group, genetic makeup or disease predisposition,
among other variables. While selecting relatively similar partici-
pants can increase the statistical power of the study, it often comes
at the cost of fewer participants or a loss of generalizability.
Other methods to reduce unwanted data variability are to
control the conditions under which samples are taken (after
fasting, for example), the length and condition of sample storage,
and the methods used for sample preparation and analysis.
2.4. Selecting a more appropriate statistical analysis
A ﬁnal way to maximize the power of a study is to select sta-
tistical methods that take the fullest possible advantage of the data
collected. One common analytical technique is to separate the
participants into groups (quintiles, for example) depending on
their risk, the strength of their response, or the level of a bio-
marker of interest, and then to compare the two most extreme
groups. Doing so frequently increases the measured intervention
effect, but it comes at the cost of only using a smaller number of
participants. In most cases it is more effective to use all the data
collected and draw conclusions from a linear model, logistic
regression to estimate risk of an outcome, or survival analysis to
study time-to-event.
In many cases it is impossible to select participants or to control
the experimental conditions to completely remove the most
important confounding variables, but it is possible to explicitly
incorporate some of these variables in the data modeling, as a way
to remove (or at least reduce) their effect on the analysis of the
parameters of interest. Some of the most important confounding
variables in cardiovascular research involving LC omega-3 fatty
acids include:
1. Socioeconomic variables: For many populations, habitual ﬁsh
intake and LC omega-3 supplement use are associated with
higher socioeconomic status, which is connected with a better
standard of care and faster diagnostics.
2. Baseline EPAþDHA levels: As described previously, the effect of
an intervention frequently depends on baseline levels, so it
makes sense to consider this variable during ﬁnal analysis.
3. Use of medication: The standard of care for both primary and
secondary cardiovascular prevention has changed dramatically
in recent years, with more patients at risk for cardiovascular
events taking lipid lowering and other cardio-protective med-
ications, and use of these drugs may overwhelm the true effect
of LC omega-3 fatty acids. A subgroup analysis of the meta-
analysis in Kwak et al. [26] showed LC omega-3 supplementa-
tion to have a stronger cardio-protective effect in trials where
most subjects were not already using lipid-lowering drugs. It
would be difﬁcult to conduct a trial involving only participants
not already taking any of these agents, but including drug usage
in the data analysis may reduce their confounding effect.
To conclude, baseline levels of EPAþDHA intake and status, the
incidence of cardiac events, and the medical standard of care have
changed dramatically since the publication of DART [8] and GISSI
Prevenzione [9], the ﬁrst large RCTs on the effect of LC omega-3
fatty acids on cardiovascular mortality, and this has profound
implications for the design of newer trials. Study designs that were
effective 35 years ago may lack sufﬁcient power today, leading to
inconclusive results and confusion about the role of LC omega-3fatty acids in cardiovascular prevention. Researchers need to
consider these changes when planning future trials.3. Design issues for clinical trials of omega-3 products asses-
sing cardiovascular outcomes (Kevin C. Maki, PhD)
The ﬁrst observational evidence, nearly four decades ago, for a
cardioprotective effect of LC omega-3 fatty acids came from the
discovery that Greenland Inuits, who consumed a diet high in
EPAþDHA, had lower mortality from heart disease than Amer-
icans and Europeans, who consumed less of these fatty acids
[27–30]. A substantial body of epidemiological evidence for the
association between reduced cardiac events/mortality and higher
intakes (mostly from ﬁsh) and blood levels of LC omega-3 fatty
acids have accumulated since that time [31–33]. In 1999, ﬁndings
from a large-scale, open-label, RCT were published that aligned
with the observational evidence [9,34,35]. The Gruppo Italiano per
lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Pre-
venzione trial of 11,323 patients with recent (o3 months) myo-
cardial infarction results suggested that 1 g/d of LC omega-3-acid
ethyl esters signiﬁcantly reduced the risk of total mortality (rela-
tive risk [RR] 0.59, 95% conﬁdence interval [CI] 0.36–0.97,
p¼0.037) as early as three months after starting the omega-3 fatty
acids, as well as sudden cardiac death (RR 0.47, 95% CI 0.219–0.995,
p¼0.048) after 4 months, and cardiovascular, cardiac, and cor-
onary deaths after six to eight months of treatment [34,35].
In the years since the GISSI-Prevenzione trial, several RCTs have
failed to detect the same signiﬁcant cardioprotective effects,
prompting controversy and debate about the utility of LC omega-3
fatty acids for the reduction of cardiovascular risk [6,36]. Findings
from recent meta-analyses of RCT data from trials with LC omega-
3 fatty acid interventions have provided evidence for a modest
beneﬁt on risk for cardiac death, but have generally failed to show
signiﬁcant reductions in other cardiovascular disease (CVD) out-
comes [36–39].
Careful examination of the RCTs indicates, however, that there
have been several study design issues that may have biased the
results toward the null, reducing the likelihood that beneﬁcial
effects of LC omega-3 fatty acids on CVD outcomes would be
detected. Among these are 1) the use of low dosages of EPA and/or
DHA, 2) a failure to assess the LC omega-3 status of the subjects
prior to and during treatment, 3) the concurrent use of cardio-
vascular and lipid-altering medication(s) that might have over-
whelmed the effects of the omega-3 fatty acids, and 4) a lack of
clarity as to which mechanisms were expected to produce bene-
ﬁts. It is important to consider these points so that future clinical
trials can be designed in a manner that optimizes the potential for
demonstrating beneﬁts, if present, of LC omega-3 fatty acid
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of the population that are most likely to beneﬁt from such
interventions.
To date, clinical trials investigating cardiovascular effects of LC
omega-3 fatty acids have generally used relatively low dosages
(median [interquartile range] 1.0 [0.5–1.8] g/d EPA and/or DHA
ethyl esters) [36]. Evidence from a subgroup analysis of the Japan
EPA Lipid Intervention Study (JELIS), which administered 1.8 g/d
EPA as ethyl esters, indicated that the greatest cardiovascular
event risk reduction occurred in subjects who achieved plasma
levels of EPA in the highest quartile (Z 150 mg/mL), whereas no
statistically signiﬁcant beneﬁt was observed in subgroups that
achieved lower levels of plasma EPA [10,40] (Fig. 4). A cohort study
reported by Mozaffarian et al. [41] showed that higher circulating
individual and total omega-3 levels were associated with lower
total mortality, especially coronary heart disease (CHD) death, and
that subjects in the highest quintile of plasma total omega-3 fatty
acids (median¼6.04%), compared to the lowest quintile (med-
ian¼3.17%), had a 27% relative reduction in total mortality. Based
on extrapolation of results from dose–response studies (e.g.,
Browning et al. [42]), it is unlikely that consumption of LC omega-
3 products providing 1 g/d EPAþDHA ethyl esters would be suf-
ﬁcient to raise mean levels of omega-3 fatty acids to the range
where the greatest beneﬁt has been observed (Z150 mg/dL
plasma EPA andZ6% for plasma phospholipid total omega-3 fatty
acids).
In many recent clinical trials examining LC omega-3 treatments
in high-risk individuals, the majority of subjects were concurrently
taking cardiovascular and/or lipid-altering medications as stan-
dard of care, and this may have overwhelmed the LC omega-3
effect. In the Outcome Reduction with an Initial Glargine Inter-
vention (ORIGIN) trial, an examination of LC omega-3 fatty acids
and cardiovascular disease outcomes in patients with dysglycemia,
for example, approximately 54% of subjects were taking a statin,
69% were taking an angiotensin converting enzyme inhibitor or
angiotensin II receptor blocker, 53% were taking a beta-blocker,
and 69% were taking aspirin [4]. Notably, a subgroup analysis of a
meta-analysis of randomized controlled trials by Kwak et al. [26]
showed a trend toward cardiovascular event risk reduction with LC
omega-3 fatty acid supplementation in the trials where the
majority of subjects were not using lipid-lowering agents (RR 0.74,
95% CI 0.54–1.03), compared to the trials in which a large per-
centage of subjects were using lipid-lowering agents (RR 1.02, 95%
CI 0.92–1.12). In future clinical trials enrolling high-risk subjects,
the potential confounding effects of concomitant use of cardio-
vascular and lipid-altering medications should be considered.
LC omega-3 fatty acids are hypothesized to produce cardio-
vascular beneﬁts through a variety of mechanisms including:
antiarrhythmic effects, lipoprotein lipid modiﬁcations, hemody-
namic changes (reduction of blood pressure and heart rate), and
antithrombotic and anti-inﬂammatory effects. The various pro-
posed mechanisms have different dose–response characteristics
that need to be considered at the trial design stage (Fig. 3).
As previously mentioned, the strongest evidence from rando-
mized trials is for reducing the risk of cardiac death, which may be
attributable to antiarrhythmic effects, particularly with regard to
reducing the propensity toward potentially fatal ventricular
arrhythmias triggered by ischemia [24,39,43,44]. Data from
observational studies suggest a possible threshold effect for the
relationship between LC omega-3 fatty acid intake and CHD death.
In a pooled analysis of prospective cohort studies and RCTs, a 36%
lower risk of CHD death was observed between 0 and 250 mg/d of
EPAþDHA consumption (RR 0.64, 95% CI 0.50–0.80, p¼0.94), but
little further beneﬁt was observed at intakes above 250 mg/d [24].
In recent years, LC omega-3 fatty acid intakes in the populations of
developed countries have increased due to public awareness ofpotential health beneﬁts and the availability of foods fortiﬁed with
LC omega-3 fatty acids [45]. It is notable that the estimated
median baseline intake of EPAþDHA in the ORIGIN trial, designed
to investigate the prevention of cardiovascular events in patients
with recent myocardial infarction or heart failure, was 210 mg/d,
which is close to the threshold of 250 mg/d suggested by the
analysis above (Fig. 2), thus, potentially reducing the ability to
detect an effect on risk for CHD death.
These results also illustrate the importance of measuring LC
omega-3 fatty acid status at baseline and during treatment in
order to exclude subjects with high baseline LC omega-3 status
who may have less potential to beneﬁt from supplemental
EPAþDHA. Another reason for measuring LC omega-3 fatty acid
status during and after treatment is to provide a physiological
measurement for conﬁrmation of compliance with the LC omega-3
fatty acid intervention.
The low dosages used in most LC omega-3 intervention studies
are below the range recommended for management of hyper-
triglyceridemia of 2–4 g/d of EPAþDHA [46,47]. In addition, the
trials completed to date were not designed to assess whether the
lipid-altering effects of LC omega-3 fatty acids reduce CVD mor-
bidity and mortality, both because of the low dosages employed,
and because they did not select participants based on the presence
of hypertriglyceridemia. In hypertriglyceridemic subjects, ther-
apeutic dosages of EPAþDHA typically reduce triglyceride (TG)
and very low-density lipoprotein cholesterol levels, and modestly
increase high-density lipoprotein cholesterol (HDL-C) [48]. These
levels of intake generally have a neutral effect on low-density
lipoprotein cholesterol (LDL-C), but may raise LDL-C in some,
primarily those with severe hypertriglyceridemia [49,50]. In the
JELIS trial, a particularly strong reduction in cumulative incidence
of major coronary events was observed in the subgroup with
TGZ150 mg/dL and HDL-Co40 mg/dL (hazard ratio 0.47, 95% CI
0.23–0.98, p¼0.043) [51]. Omega-3 fatty acids alter lipoprotein
lipids in a manner similar to the effects of ﬁbric acid medications
[49,50,52]. Subgroup analyses from trials of ﬁbric acids have also
shown that the subjects with high TG plus low HDL-C had sig-
niﬁcant reductions in CHD risk, which was generally larger than
observed in participants without the high TG/low HDL-C pheno-
type [53–55]. Thus, a trial to test the efﬁcacy of LC omega-3 fatty
acids as lipid-altering agents would ideally employ a dosage of EPA
or EPAþDHA in the 2–4 g/d range, and enroll participants with the
high TG/low HDL-C phenotype.
In conclusion, investigators designing outcomes trials should
carefully consider several study design issues in order to effec-
tively investigate the efﬁcacy of LC omega-3 fatty acids for CVD
risk reduction.
1. An adequate LC omega-3 fatty acid dose should be used to
produce the mechanistic change(s) through which a cardiovas-
cular beneﬁt might be anticipated.
2. An appropriate study population should be enrolled to test the
hypothesized effect; e.g., high-CVD risk subjects with low LC
omega-3 status at baseline. To test the efﬁcacy of the lipid-
altering effects of omega-3 fatty acids, subjects should be
enrolled with high TG and low HDL-C.
3. Consideration is needed of the possible effects of cardiovascular
medications in higher risk subjects, and the potential of these
agents to confound the effect of the LC omega-3 intervention.
4. Measurement of LC omega-3 status should be performed at
baseline and during treatment to ensure that subjects studied
have low baseline LC omega-3 fatty acid status, and to allow
assessment of compliance with the intervention.
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PhD)
To increase the odds of detecting an effect in a clinical study of
LC omega-3 fatty acids with cardiovascular outcomes, low (nor-
mal) EPAþDHA status should be an inclusion criterion. Fatty acid
status can be measured in a variety of tissues, most commonly
from the blood. Fatty acids in the blood are found in the plasma
(50%), red blood cells (50%) and white blood cells and platelets
(o1%). In plasma, the fatty acids are found in 4 main lipid classes:
phospholipids (45%), cholesteryl esters (11%), triglycerides
(42%) and non-esteriﬁed fatty acids (4%). Red blood cell (RBC),
white blood cell and platelet fatty acids are virtually all carried in
membrane phospholipids.
In general, a circulating (e.g. plasma, platelets, monocytes, and
RBC) fatty acid measurement of LC omega-3 fatty acids is going to
provide a reasonably good indication of LC omega-3 fatty acid
status, as demonstrated in a recent study [42].
There are advantages and disadvantages associated with each
sample type used for the analysis of LC omega-3 fatty acid status
(Table 2). With respect to ease of use in the clinical laboratory,
whole plasma (or serum), whole blood and red blood cells rank
the highest, followed by plasma phospholipids (or PL subclasses)
and plasma cholesteryl esters. The most logistically/analytically
challenging sample types include: platelets, leukocytes, adipose
tissue and cheek swabs.
Based on our work over the last 10 years, we have found that
the RBC fraction has several advantages over other blood-based
metrics for tracking LC omega-3 fatty acid status. As originally
proposed in 2004, the “Omega-3 Index” was deﬁned as the
EPAþDHA content of RBCs expressed as a percent of total identi-
ﬁed fatty acids, as described elsewhere [57–60]. Several reviews
have discussed the clinical utility [61] and the research utility [62]
of the Omega-3 Index, and the extent to which it fulﬁlls the cri-
teria for a risk factor for CVD [63].
In addition to there being multiple sample types in which LC
omega-3 fatty acid status can be estimated, there are multiple
ways of expressing the LC omega-3 fatty acid content of the same
sample type. Using either whole blood or RBCs as examples, where
the Omega-3 Index is calculable, Lands has proposed using the
ratio of n-3 HUFA (highly unsaturated fatty acids) to total HUFA
[64]. Whether in whole blood or in RBCs, these two metrics are
very highly correlated. Using data from the Heart and Soul Study
[65], and from the Framingham Offspring Study [66], we have
shown correlation coefﬁcients of 0.93 and 0.95, respectively [56].
Consequently, one could use either metric to get an idea of omega-
3 status. An 8% Omega-3 Index, which is the target cardioprotec-
tive level [57], corresponds to a 40% n-3 HUFA to total HUFA ratio.Table 2
Sample types used to assess LC omega-3 fatty acid status. Adapted with permission of
Tissue Comment
Whole plasma (serum) Includes all lipid classes (CE, PL, triglycerides, free fatt
High biological variability but no lipid class separatio
Plasma phospholipids (PL) More enriched in LC omega-3 fatty acids than whole p
high biological variability, and requires lipid class sep
Plasma cholesteryl esters (CE) Carries EPA, with very little DHA, and requires lipid c
Whole blood Includes plasma (with all lipid classes) and cells, henc
plasma PL; and requires no lipid class separation
Red blood cells Easily recovered and no lipid class separation necessar
½ life of any circulating sample type
Platelets More steps in recovery than plasma or RBC, but no lip
Leukocytes Special methods needed to isolate, but no lipid class
Adipose tissue Challenging to collect, and not available in the clinica
Cheek swabs Non-invasively collected but time-consuming preparaRed blood EPAþDHA content has a low biological (or intra-
individual) variability, as well as being a long-term marker of LC
omega-3 fatty acid status. To explore this, LC omega-3 fatty acid
status fromwhole blood, whole plasma, plasma phospholipids and
RBCs was measured in 20 healthy, free living volunteers for six
consecutive weeks [67]. Intra-individual variability of EPAþDHA
for the different sample types was as follows: RBCs 4.1%, whole
blood 6.7%, plasma 16% and plasma phospholipids 15%. Thus, the
RBC biological variability was ¼th of that of plasma.
In addition to being associated with low biological variability,
RBCs are also impervious to acute intakes of LC omega-3 fatty
acids. In clinical practice in particular, it is important to use a
marker that is not acutely altered from normal by a single large
intake of fatty ﬁsh or ﬁsh oil because it can be misleading. To
examine this question, we recruited another 20 healthy volunteers
and tested them ﬁve times over 24 hours after giving them a
breakfast including 3.4 g of EPAþDHA [68]. The percent change
from baseline was calculated at each time point for RBC EPAþDHA
(% of total), plasma EPAþDHA (% of total), and plasma EPAþDHA
concentration (μg/mL). While both plasma EPAþDHA (% of total)
and plasma EPAþDHA concentration (μg/mL) increased by 20–40%
within six hours, Omega-3 Index was unaffected. This also
demonstrates the value of the Omega-3 Index to reﬂect usual
intake as opposed to acute deviations from usual. In this regard,
the Omega-3 Index may be compared with hemoglobin A1c test-
ing in diabetes. Compared to plasma glucose levels which can vary
markedly within an individual during the day, the hemoglobin A1c
test (which, like the Omega-3 Index, is measured in RBCs and
expressed as a percent) is a far more stable reﬂection of the
patient’s usual glycemic status. The same may be said for the
Omega-3 Index with respect to omega-3 fatty acid status.
Even using the same sample type (e.g., RBCs), omega-3 testing
methods need to be standardized because of differences in
methods (reagents, temperatures, timing, sequence of solvent
addition, which fatty acids are included in the total, etc.) To
demonstrate at least that different labs give different results, ﬁve
U.S. commercial labs were sent the same blood sample and asked
to measure the level of EPAþDHA in RBCs. The results demon-
strated a difference of þ32% to 63%, i.e. results differed by a
factor of 3.5 from what is called the “HS-Omega-3 Indexs” tech-
nology (i.e., the speciﬁc method described in Harris et al. [69]). It is
safe to assume that the same applies to other non-commercial
laboratories. The reasons for these differences are unknown (since
the other laboratories do not publish their methods), but the point
remains that major differences between laboratories exist. In the
absence of standardization, it is important that the same labora-
tory and the same method are used to measure the pre- and post-
intervention samples from within any trial.Nova Science Publishers, Inc. from [56].
y acids) and thus variations in plasma lipoprotein levels may affect composition.
n required
lasma and reasonably reﬂective of tissue PL fatty acid composition, but relatively
aration
lass separation
e more enriched in PL than plasma; lower biological variability than plasma or
y; essentially pure PL. Low biovariability and reﬂects tissue composition. Longest
id class separation necessary; essentially pure PL. Shorter ½ life than RBCs
separation necessary; essentially pure PL. Shorter ½ life than RBCs
l setting. Essentially pure TG, low content of EPA and DHA
tion and isolation. No lipid class separation necessary; essentially pure PL
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omega-3 fatty acids in a clinical study with cardiovascular out-
comes, low EPAþDHA status should be an inclusion criterion.
While LC omega-3 fatty acid status can be determined by several
different approaches, in our view the Omega-3 Index (i.e., RBCs
analyzed for EPAþDHA by the HS-Omega-3 Indexs technology)
has many advantages.5. Omega-3 status and study design (Clemens von Schacky,
MD)
Epidemiologic studies demonstrated an inverse relation of
occurrence of severe events like death, sudden cardiac death, fatal
and non-fatal myocardial infarctions and intake of EPAþDHA, be it
in the form of ﬁsh or dietary supplements [70,71]. In contrast,
meta-analyses of large RCTs focusing on the same endpoints
demonstrated no effect of intake of EPAþDHA, with most trials
performed with dietary supplements [38]. As a result, some, but
not all guidelines of cardiac societies recommend EPA and DHA for
prevention of cardiac events, either in the form of fatty ﬁsh or as
dietary supplements [72,73]. The following paragraphs focus on
the discrepancies between epidemiologic ﬁndings and results of
intervention trials, try to explain them, and, based on these
explanations, suggest novel approaches in designing intervention
trials.
5.1. Epidemiology: intake vs. levels
A recent systematic review and meta-analysis of observational
and intervention studies found in a total of 422,786 participants
with 9089 coronary events (like fatal and non-fatal myocardial
infarction, coronary death, angina and others) that the highest
tertile of intake of EPAþDHA was associated with a 13% lower risk
for coronary events (relative risk, RR 0.87, 95% conﬁdence interval,
CI, 0.78–0.97), as compared to the lowest tertile [38]. However,
when levels were assessed in 20,809 participants with 4073
events, the highest tertile of levels of EPAþDHA (measured in
whole blood, serum, plasma, erythrocytes or adipose tissue) was
associated with a 25% lower risk for coronary events (RR 0.75, 95%
CI 0.62–0.89), as compared to the lowest tertile [38]. Similar
ﬁndings have been reported elsewhere, as reviewed in [70,71].
Why is it that the relative risk associated with LC omega-3 fatty
acid intake is different from the relative risk associated with LC
omega-3 fatty acid levels?
Some 50% of participants in observational studies on diet do
not report plausible data [74]. In contrast to estimates of dietary
intake, blood levels of LC omega-3 fatty acids are not subject to
recollection bias, and other subjective inﬂuences, and therefore, a
clearer picture is likely to emerge. However, assessing blood levels
of LC omega-3 fatty acids is subject to biological and analytical
variabilities: pre-analytical, analytical, and post-analytical pro-
blems, such as biological variability, storage conditions and issues
of analytical quality management. Few studies have formally
compared biologic variabilities of blood compartments, but in one
study, the biological variability of erythrocytes was found to be
1.3%, substantially lower than the biological variabilities of whole
blood (5.7%), whole plasma (13.6%) or plasma phospholipids
(13.9%) [67]. The low biological variability of erythrocyte fatty acid
composition could only be discerned with a method with a low
analytical variability. A speciﬁc analytical method (HS-Omega-3
Indexs), standardizing every step of sample preparation, gas-
chromatographic analysis and evaluation of the chromatogram
brought analytical variability down to 3.9% [67,70,71]. Since it
correlates strongly with the EPAþDHA contents of phospholipids
in many tissues, the HS-Omega-3 Indexs assesses an individual’sstatus of EPAþDHA [70,71]. With the use of this method, it was
found that overall mortality was 7% in the lowest tertile, and 26%
in the highest tertile of erythrocyte EPA in the ﬁrst two years in
1144 patients after a myocardial infarction (unadjusted for con-
ventional risk factors, with adjustment for conventional and
unconventional cardiovascular risk factors [75]. Studies in other
populations had similar results [70,71]. As discussed in more detail
elsewhere, a low HS-Omega-3 Indexs fulﬁlls almost all criteria of
a cardiovascular risk factor, according to current criteria of the
American Heart Association, except that there is not a HS-Omega-
3 Indexs-based intervention trial with clinical endpoints [70,71].
5.2. Levels and neutral results of previous intervention trials
For previous intervention trials with clinical endpoints, parti-
cipants were recruited irrespective of their baseline status in EPA
and DHA, both in the cardiovascular area and in other ﬁelds.
Moreover, in most large cardiovascular trials, no material was
stored to make later analyses of status of EPA and DHA possible,
neither at baseline nor during the trial, with two exceptions [2,11].
This was like conducting a trial with a blood pressure lowering
agent without measuring blood pressure, or with a lipid lowering
agent without measuring blood lipids, neither at baseline nor
during the trial. In all populations studied so far, erythrocyte
EPAþDHA had a statistically normal distribution, with a varying
proportion of individuals in the target range suggested for the HS-
Omega-3 Indexs of 8–11% [70,71]. Demonstrating an effect of
EPAþDHA in individuals with a high status in EPAþDHA at
baseline will be difﬁcult, if not impossible. Since cardiovascular
disease is multifactorial, and has a high prevalence, it is not
expected that individuals with cardiovascular disease will have a
vastly lower status in EPAþDHA than the population at large.
Indeed, this is what we found with the HS-Omega-3 Indexs
[70,71]. This reasoning indicates that recruiting trial participants
for LC omega-3 intervention trials, irrespective of baseline omega-
3 status is likely to bias the results toward the null for cardiovas-
cular outcomes, as well as for other multi-factorial diseases.
What was just discussed is compounded by the inter-individual
variability in response in terms of status to a given dose of
EPAþDHA: When 40 individuals with a HS-Omega-3 Indexso5%
were given 0.5 g EPAþDHA/day, their mean HS-Omega-3 Indexs
increased signiﬁcantly, but the increase varied by a factor of 13
inter-individually [76], which could be due to genetic variants [77].
Translated to clinical trials, this indicates that levels of EPAþDHA
will overlap between the intervention and the control or placebo
groups. Indeed, this has been observed, when investigated, with
omega-3 levels of the intervention group and the placebo group
overlapped in up to 80% of study participants [25,78]. One of the
most important issues in an intervention trial is the distinction
between intervention and control or placebo groups in terms of
the intervention. With a large proportion of study participants
being undistinguishable in terms of EPAþDHA levels, it is a small
wonder that an effect of an intervention cannot be discerned.
Bioavailability of EPAþDHA depends on the amount of fat of
the concurrent meal (if any), whether or not, and how, the
EPAþDHA were emulsiﬁed, other matrix effects, and to a
much lesser degree on the molecule in which they are bound
(in the following order: phospholipids4recombined trigly-
cerides4triglycerides4free fatty acids4ethyl ester; this issue is
discussed in more detail elsewhere [70,71,79]). All recent large
trials with EPAþDHA in the cardiovascular ﬁeld advised their
participants to ingest the LC omega-3 fatty acid supplement with
breakfast [70,71]. In many countries, breakfast is a low-fat meal
[70,71]. In almost all large trials, EPAþDHA were used in capsules,
i.e. in an unemulsiﬁed form [70,71]. In most cases, the omega-3
ethyl ester was used [70,71]. Taken together, unintentionally,
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mized. As mentioned, blood levels were not measured in most
large trials, and, in most cases, no material was stored for that
purpose, so it will remain impossible to prove this point by mea-
suring levels.
Moreover, there appear to be experts in large clinical trials,
distinct from experts in the ﬁeld that the trials are conducted in:
When the OMEGA trial was designed [3], this author was given the
study protocol, but no opportunity to criticize it. On several
occasions, but to no avail, this author actively sought to support
the design of other large cardiovascular trials, designed by indi-
viduals not conversant with the ﬁeld. Taken together, trial
designers did not appear to be conversant with the ﬁeld of LC
omega-3 fatty acids, and did not appear to be willing to seek, let
alone heed, the advice of an expert. The resulting neutral results of
the large cardiovascular trials indicate that it is not possible to
design and conduct a successful trial without expertise in the
difﬁcult ﬁeld of LC omega-3 fatty acids.
5.3. Levels and design of future intervention trials
Future intervention trials can be expected to provide clearer
results if the issues just mentioned are taken into consideration,
and the following design features are incorporated:
 Recruitment of participants with low baseline LC omega-3 fatty
acid levels,
 Treatment to a pre-deﬁned target level. Since the HS-Omega-3
Indexs has the largest database of all methods to measure
levels to support its use, use of its target range of 8–11% is a
distinct possibility. Since levels in erythrocytes reach a new
equilibrium after approximately three months, this calls for
measuring levels some three months into the study, and
adjusting the dose of LC omega-3 fatty acids individually. To
maintain blinding, doses of placebo will need to be adjusted
accordingly. This approach will generate a separation of inter-
vention and control or placebo group in terms of LC omega-3
fatty acid levels.
 Taking bioavailability issues into account, e.g. by advising par-
ticipants to take capsules with the main meal containing sufﬁ-
cient fat to enhance LC omega-3 bioavailability, and/or use of an
emulsion.
 All this reasoning, however, will be futile, if clinical trials con-
tinue to be designed by experts in clinical trials, not drawing on
expertise from the ﬁeld of LC omega-3 fatty acids.
5.4. Positive results of previous studies
In some health issues, like major depression or impaired cog-
nitive functions, intervention trials with EPAþDHA produced
positive results [80–82]. Of note, in individuals with these health
issues, a low status in EPA and DHA has been found [70,71,83].
Therefore, the odds were increased for positive ﬁndings from
intervention with EPAþDHA. However, the other points just dis-
cussed (in “Levels and design of future intervention trials”) were not
part of the design of the previous intervention trials in major
depression or impaired cognitive function. Thus, these trials might
have substantially underestimated the potential effects of
EPAþDHA.
5.5. Conclusions
Measuring levels of LC omega-3 fatty acids has unraveled
substantial deﬁcits in the design of previous large intervention
trials with cardiovascular clinical endpoints, as well as for trials in
other therapeutic areas. In the cardiovascular ﬁeld, these deﬁcitsare thought to be the reason for the overall neutral results.
Learning from these deﬁcits, and incorporating the lessons learned
into the design of future trials can substantially increase the
impact and the chance of success for future trials.6. Patterns of omega-3 intake and omega-3 and -6 status
(Philip C. Calder, PhD)
In commonwith other fatty acids, EPA and DHA are transported
in the bloodstream as components of lipoproteins, in which they
are esteriﬁed into triacylglycerols, phospholipids and cholesteryl
esters, or non-covalently linked with albumin in the non-esteriﬁed
form. EPA and DHA are stored in adipose tissue esteriﬁed into
triacylglycerols and they are found in all cell membranes esteriﬁed
into phospholipids and related complex lipids. Thus, EPA and DHA
occur within transport pools (plasma lipoproteins and non-
esteriﬁed fatty acids), functional pools (cell membranes) and the
storage pool (adipose tissue). The proportional contribution of EPA
or DHA to the total fatty acids present within any of the transport,
functional or storage pools differs according to the pool, and in
most locations there is a greater contribution from n-6 fatty acids
than from LC omega-3 fatty acids, reﬂecting in part the greater
intake from the diet of the former. For example in human per-
ipheral blood mononuclear cells (a mixture of lymphocytes and
monocytes), linoleic, dihomo-gamma-linolenic and arachidonic
acids contributed an average of 10%, 1.5% and 20% of total fatty
acids, respectively [84]. In contrast, EPA and DHA contributed an
average of approximately 1 and 2.5%, respectively [84]. Similar
differences are seen in other blood cell types like platelets, neu-
trophils and erythrocytes and in tissues like heart, liver, skeletal
muscle and gut mucosa. An exception is brain and eye which have
high DHA contents [85–87]. In most cells and tissues, DHA is
present in a greater proportion than EPA; this is especially so in
the brain and eye [85–87]. Increasing the intakes of EPA and DHA
from ﬁsh or from LC omega-3 fatty acid supplements is reﬂected in
increased proportions of both fatty acids in blood lipid, blood cell,
and many tissue pools. Sands et al. [88] reported a signiﬁcant
positive relationship between habitual ﬁsh intake and erythrocyte
Omega-3 Index in a cross-sectional study of 163 men and women
of a wide age range; the index averaged 3% in those individuals
who reported eating ﬁsh less than once per month, and increased
to an average of 7% in those reporting eating ﬁsh at least twice per
week. Trials with LC omega-3 fatty acid supplements have
demonstrated the possibility of marked increases in EPA and DHA
content of blood lipids [42,84,89–95], various blood cells types
including platelets [42,89,96], white cells [42,84,93,94,97,98] and
red cells [42,91,92,95], and various tissues including skeletal
muscle [99], heart [100], gut mucosa [101–103] and adipose tissue
[42,92] when their intake is increased. These locations all show a
dose- and time-dependent incorporation of both EPA and DHA
[42,84,89,92–94,97], but the precise pattern depends upon the
speciﬁc location. Pools that are turning over rapidly show faster
incorporation of EPA and DHA than slower turning over pools.
Thus, plasma lipids incorporate EPA and DHA more quickly than
blood cells do [84,92], whilst amongst blood cells, platelets and
leukocytes have been usually shown to incorporate EPA and DHA
more quickly than erythrocytes. A recent study examined in detail
the dose- and time-dependent appearance of EPA and DHA in
different transport, functional and storage pools in humans [42].
Healthy human volunteers consumed one of three doses of
EPAþDHA (providing 3.27, 6.54 or 13.08 g per week; the ratio of
EPA to DHAwas 1:1.1 and they were provided in the triacylglycerol
form) in capsules or placebo capsules daily for 12 months. Blood
was collected at the start of the study and at several intervals up to
12 months; in addition adipose tissue biopsies were collected at
Fig. 5. Time course of changes in EPA and DHA content of human plasma phosphatidylcholine and platelets in subjects consuming placebo oil or one of three doses of ﬁsh
oil. Healthy subjects supplemented their diet with capsules providing 0, 3.27, 6.54 or 13.08 g EPAþDHA per week for a period of 12 months; the ratio of EPA to DHAwas 1:1.1.
Plasma phosphatidylcholine and platelets were isolated at 0, 1, 2, 4, 8, 12, 24, 36 and 52 weeks and their fatty acid composition determined by gas chromatography. Data are
mean7standard error from at least 30 subjects per group. Reproduced from [42] with permission of American Society for Nutrition.
Table 3
Estimated time to peak incorporation and maximum incorporation of EPA and DHA in different transport, functional and storage pools in healthy humans with low fatty ﬁsh
intake. Data are median from 33 individuals who consumed 13.08 g EPAþDHA per week for 12 months. The ratio of EPA to DHA was 1:1.1 and EPA and DHA were taken over
4 days of each week. Adapted with permission of American Society for Nutrition from [42].
Pool EPA DHA
Time to
peak (days)
Maximum incorporation (%
of fatty acids)
Increase from base-
line (% of fatty acids)
Time to
peak (days)
Maximum incorporation (%
of fatty acids)
Increase from base-
line (% of fatty acids)
Plasma phosphatidylcholine 18 3.5 2.5 23 5.9 2.5
Plasma cholesteryl ester 24 3.2 2.2 ND 1.0 0.4
Plasma triacylglycerol 16 1.7 2.0 20 2.5 2.0
Plasma non-esteriﬁed fatty acid 38 1.1 0.5 32 3.1 2.0
Blood mononuclear cells 249 2.3 1.6 207 3.3 1.5
Erythrocytes 55 3.7 2.0 136 7.7 3.0
Platelets 25 3.1 2.2 32 3.6 2.0
Subcutaneous adipose tissue 4365 0.3 0.1 4365 0.35 0.15
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investigated showed time- and dose-dependent incorporation of
both EPA and DHA and that, in time, pools reach a new steady
state content of EPA and DHA that is determined by intake, but
that the exact nature of these changes varies among pools. Fig. 5
shows the incorporation of EPA and DHA into plasma phosphati-
dylcholine and into platelets. EPA is incorporated more quickly
than DHA into both pools, the incremental increase in both fatty
acids is greater in plasma phosphatidylcholine than in platelets,
and the new steady state level of EPA and DHA that is reached is
precisely related to the dose of EPA or DHA being consumed.
Table 3 summarises the time to reach a new steady state and the
approximate increment in EPA and DHA content (as a proportion
of total fatty acids) that the new steady state represents. Although
some studies report greater incorporation of EPA and DHA into
blood lipids in women than men [104] and greater incorporation
in older than younger adults [93], this recent study saw no dif-
ferences between sexes or across age groups [105].
The participants in the study of Browning et al. [42] took their
LC omega-3 fatty acid supplements on one, two or four days a
week, consuming placebo capsules on the other days. Anadditional ﬁfth group in the study consumed 6.54 g EPAþDHA per
week but spread evenly across all days of the week [106]. This
enabled the EPA and DHA incorporation pattern to be compared
between 6.54 g EPAþDHA spread across two days, or across seven
days of the week to be compared. The increases in EPA and DHA in
plasma phosphatidylcholine, platelets and blood mononuclear
cells were greater in the group consuming the EPA and DHA every
day compared with the group consuming the fatty acids at a
higher daily intake but on fewer days [106]. The ﬁndings suggest
that regular, frequent intake of moderate amounts of EPA and DHA
will achieve a higher status than less frequent intake of higher
amounts.
The higher status of EPA and DHA achieved through increased
intake of EPA and DHA is maintained so long as the higher intake
of EPA and DHA is maintained. If, after a period of increased intake
of EPA and DHA, intake returns to the earlier lower levels, then
EPA and DHA status decline, eventually returning to earlier levels.
This is well described for blood lipids [84,89,92], platelets [89],
leukocytes [84] and erythrocytes [95]. However, just as the
incorporation of EPA into different pools is faster than the incor-
poration of DHA, the loss of EPA is faster than the loss of DHA. Loss
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Since EPA and DHA content in lipid pools is frequently described as
a percentage or proportion, the increase in content of these fatty
acids is accompanied by a decrease in content (proportion) of
other, usually unsaturated, fatty acids. Depending upon the pool,
since once again there are differences among pools, these other
fatty acids include oleic, linoleic, dihomo-gamma-linolenic and
arachidonic acids. There are good demonstrations of dose- and
time-dependent decreases in the proportion of arachidonic acid in
leukocytes and platelets [89,93,97].
Admittedly, we do not fully understand the importance of
EPAþDHA status in relation to the status of other biologically
active fatty acids. While it is conceivable that EPA and DHA may
interfere with beneﬁcial effects of other fatty acids, the increased
status of EPA and DHA seen with modestly increased intake has
only a fairly small impact on the status of other fatty acids [107].Disclosure
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Society for the Study of Fatty Acids and Lipids (ISSFAL). The event
was sponsored by the Global Organization for EPA and DHA
Omega-3s (GOED). This report is not a consensus statement;
therefore, some authors may not agree with all the opinions
expressed herein.References
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